Chiltern has acquired Pacific Clinical Research, a pan-Asian CRO based in Singapore. The acquisition allows Chiltern to offer services throughout the Asia-Pacific region and expands its oncology and anti-infective offerings. The combined company adds direct capabilities in Hong Kong, Korea, Malaysia, Philippines and Thailand, expanding Chiltern’s existing operations in India, Australia, Singapore and Taiwan.
 
Pacific Clinical Research founders Robert Teoh MD and Vonny Iskandar will serve as managing director, Asia-Pacific, and vice president, Asia-Pacific respectively, and will join Chiltern’s management team
 
Chiltern chief executive officer Dr. James Esinhart and chief operating officer Aize Smink commented, “We have worked with Robert Teoh for many years and our two organizations have always collaborated well. We have been looking for some time to strengthen Chiltern’s direct presence in the Asia-Pacific region, so we jumped at the opportunity to acquire Pacific and bring Robert and his team into Chiltern. We are very pleased to be able to offer customers the benefits of our merged offering with expanded access to patients and experienced research sites around Asia-Pacific.”
 
Dr. Robert Teoh added, “I am delighted to be joining the Chiltern team. Pacific Clinical Research has seen strong growth over four years and it was time for the business to integrate into a larger platform. I am excited to be leading Chiltern in the Asia-Pacific region and to be participating globally in specialized studies.”

Chiltern also recently acquired Ockham, a specialist oncology and resourcing CRO, in July.